HEK293 cell culture media study towards bioprocess optimization: Animal derived component free and animal derived component containing platforms

Journal of Bioscience and Bioengineering

Volumn 117, Issue 4, 2014, Pages 471-477

  Liste Calleja, Leticia ^a   Lecina, Martí ^a   Cairó, Jordi Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cell culture media; HEK293; High cell density culture; Recombinant adenovirus; Suspension cell culture

Indexed keywords

ANIMALS; BATCH CELL CULTURE; CELLS; CYTOLOGY; OPTIMIZATION; PRODUCTIVITY;

CELL CULTURE MEDIA; HEK-293; HIGH CELL DENSITY CULTURES; RECOMBINANT ADENOVIRUS; SUSPENSION CELL CULTURE;

ANIMAL CELL CULTURE;

ADENOVIRUS; ADENOVIRUS INFECTION; ARTICLE; BATCH CELL CULTURE; BIOPROCESS; CELL CONCENTRATION; CELL COUNT; CELL CULTURE; CELL DENSITY; CELL GROWTH; CELL KINETICS; CELL SCREENING; CELL STRAIN HEK293; CELL VIABILITY; CELLULAR PARAMETERS; CONTROLLED STUDY; CULTURE MEDIUM; DIET SUPPLEMENTATION; EMBRYO; GROWTH RATE; HUMAN; HUMAN CELL; NONHUMAN; PROCESS OPTIMIZATION; VIRAL PHENOMENA AND FUNCTIONS; VIRAL PRODUCTIVITY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; MAMMALIA;

CELL CULTURE MEDIA; HEK293; HIGH CELL DENSITY CULTURE; RECOMBINANT ADENOVIRUS; SUSPENSION CELL CULTURE;

ADENOVIRIDAE; ANIMALS; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; CELL COUNT; CELL CULTURE TECHNIQUES; CULTURE MEDIA; HEK293 CELLS; HUMANS;

EID: 84895867250     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2013.09.014     Document Type: Article

References (36)

1. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol. J. 2008, 3:90-97.
2. Jenkins N., Murphy L., Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol. Biotechnol. 2008, 39:113-118.
3. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
4. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22:1393-1398.
5. Lang R. Biosimilars and follow-on biologics: world market 2012-2022. Biosimilars and follow-on biologics: world market 2012, Visiongain, London. G. Low (Ed.).
6. Lim Y., Wong N.S.C., Lee Y.Y., Ku S.C.Y., Wong D.C.F., Yap M.G.S. Engineering mammalian cells in bioprocessing - current achievements and future perspectives. Biotechnol. Appl. Biochem. 2010, 55:175-189.
7. Dinnis D.M., James D.C. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?. Biotechnol. Bioeng. 2005, 91:180-189.
8. Browne S.M., Al-Rubeai M. Selection methods for high-producing mammalian cell lines. Trends Biotechnol. 2007, 25:425-432.
9. Chen K., Liu Q., Xie L., Sharp P.A., Wang D.I. Engineering of a mammalian cell line for reduction of lactate formation and high monoclonal antibody production. Biotechnol. Bioeng. 2001, 72:55-61.
10. Zustiak M.P., Dorai H., Betenbaugh M.J., Sauerwald T.M. Controlling apoptosis to optimize yields of proteins from mammalian cells. Methods Mol. Biol. 2012, 801:111-123.
11. Dietmair S., Nielsen L.K., Timmins N.E. Engineering a mammalian super producer. J. Chem. Technol. Biotechnol. 2011, 86:905-914.
12. Burgener A., Butler M. Medium development. Cell culture technology for pharmaceutical and cell-based therapies 2006, 41-80. CRC Press, Boca Raton. S. Ozturk, W.S. Hu (Eds.).
13. Abu-Absi N.R., Kenty B.M., Cuellar M.E., Borys M.C., Sakhamuri S., Strachan D.J., Hausladen M.C., Li Z.J. Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnol. Bioeng. 2011, 108:1215-1221.
14. Lecina M., Soley A., Gràcia J., Espunya E., Làzaro B., Cairó J.J., Gòdia F. Application of on-line OUR measurements to detect actions points to improve baculovirus-insect cell cultures in bioreactors. J. Biotechnol. 2006, 125:385-394.
15. Grosvenor S. A new era in cell culture media development. BioPharm Int. 2012, 25:28-35.
16. Keenan J., Pearson D., Clynes M. The role of recombinant proteins in the development of serum-free media. Cytotechnology 2006, 50:49-56.
17. Grillberger L., Kreil T.R., Nasr S., Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol. J. 2009, 4:186-201.
18. Chu L., Robinson D.K. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 2001, 12:180-187.
19. Lin S., Talbot P. Methods for culturing mouse and human embryonic stem cells. Methods Mol. Biol. 2011, 690:31-56.
20. Lasaro M.O., Ertl H.C.J. New insights on adenovirus as vaccine vectors. Mol. Ther. 2009, 17:1333-1339.
21. Ferreira T.B., Alves P.M., Aunins J.G., Carrondo M.J.T. Use of adenoviral vectors as veterinary vaccines. Gene Ther. 2005, 12:73-83.
22. Abedi M.R. Gene therapy clinical trials worldwide to 2007 - an update. J. Gene Med. 2007, 9:833-842.
23. Nadeau I., Kamen A. Production of adenovirus vector for gene therapy. Biotechnol. Adv. 2003, 20:475-489.
24. Geisse S., Fux C. Recombinant protein production by transient gene transfer into Mammalian cells. Methods Enzymol. 2009, 463:223-238.
25. Baldi L., Hacker D.L., Adam M., Wurm F.M. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol. Lett. 2007, 29:677-684.
26. Ruiss R., Jochum S., Wanner G., Reisbach G., Hammerschmidt W., Zeidler R. A virus-like particle-based Epstein-Barr virus vaccine. J. Virol. 2011, 85:13105-13113.
27. Costa M., Malhó R., Gonçalves J., Ferreia G. Development of a 293T cell line for the production of virus like particles in bioreactors. Animal cell technology meets genomics 18th ESACT Proceedings 2005, 325-328. Springer, Dordrecht. F. Gòdia, M. Fusseneger (Eds.).
28. Nehlsen K., Schucht R., Da Gama-Norton L., Krömer W., Baer A., Cayli A., Hauser H., Wirth D. Recombinant protein expression by targeting pre-selected chromosomal loci. BMC Biotechnol. 2009, 9:100-112.
29. Condit R.C. Principles of virology. Fields virology 2007, 25-58. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
30. Gálvez J., Lecina M., Solà C., Cairó J.J., Gòdia F. Optimization of HEK-293S cell cultures for the production of adenoviral vectors in bioreactors using on-line OUR measurements. J. Biotechnol. 2012, 157:214-222.
31. Altaras N.E., Aunins J.G., Evans R.K., Kamen A., Konz J.O., Point W. Production and formulation of adenovirus vectors. Adv. Biochem. Eng. Biotechnol. 2005, 99:193-260.
32. Lecina M., Tintó A., Gálvez J., Gòdia F., Cairó J.J. Continuous perfusion culture of encapsulated hybridoma cells. J. Chem. Technol. Biotechnol. 2011, 86:1555-1564.
33. Iyer P., Ostrove J.M., Vacante D. Comparison of manufacturing techniques for adenovirus production. Cytotechnology 1999, 30:169-172.
34. Dormond E., Perrier M., Kamen A. From the first to the third generation adenoviral vector: what parameters are governing the production yield?. Biotechnol. Adv. 2009, 27:133-144.
35. 2, and temperature effect on R-adenovirus production. Biotechnol. Prog. 2003, 19:202-208.
36. Shen C.F., Voyer R., Tom R., Kamen A. Reassessing culture media and critical metabolites that affect adenovirus production. Biotechnol. Prog. 2010, 26:200-207.